3/5
03:24 pm
arct
Arcturus Therapeutics (ARCT) had its price target lowered by Citigroup Inc. from $66.00 to $21.00. They now have a "buy" rating on the stock.
Neutral
Report
Arcturus Therapeutics (ARCT) had its price target lowered by Citigroup Inc. from $66.00 to $21.00. They now have a "buy" rating on the stock.
3/5
09:00 am
arct
Arcturus Therapeutics to Attend Upcoming Investor Conference
Medium
Report
Arcturus Therapeutics to Attend Upcoming Investor Conference
3/4
01:39 pm
arct
Arcturus Therapeutics (ARCT) had its price target raised by Citigroup Inc. from $7.00 to $8.00. They now have a "neutral" rating on the stock.
Low
Report
Arcturus Therapeutics (ARCT) had its price target raised by Citigroup Inc. from $7.00 to $8.00. They now have a "neutral" rating on the stock.
3/4
08:50 am
arct
Arcturus Therapeutics (ARCT) had its price target lowered by Piper Sandler from $72.00 to $25.00. They now have an "overweight" rating on the stock.
Low
Report
Arcturus Therapeutics (ARCT) had its price target lowered by Piper Sandler from $72.00 to $25.00. They now have an "overweight" rating on the stock.
3/4
12:15 am
arct
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings Call Highlights: Navigating Revenue ... [Yahoo! Finance]
Low
Report
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings Call Highlights: Navigating Revenue ... [Yahoo! Finance]
3/3
07:03 pm
arct
Arcturus (ARCT) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Arcturus (ARCT) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
3/3
06:25 pm
arct
Arcturus Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Arcturus Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
3/3
04:27 pm
arct
Arcturus Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
Neutral
Report
Arcturus Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
3/3
04:11 pm
arct
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress [Yahoo! Finance]
Medium
Report
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress [Yahoo! Finance]
3/3
04:01 pm
arct
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
Medium
Report
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
2/17
04:28 pm
arct
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026 [Yahoo! Finance]
Low
Report
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026 [Yahoo! Finance]
2/17
04:01 pm
arct
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
Low
Report
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
2/16
06:42 am
arct
Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]
Medium
Report
Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]
2/12
02:37 pm
arct
Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure [Seeking Alpha]
Neutral
Report
Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure [Seeking Alpha]
2/9
02:21 pm
arct
Citi Lowers Price Target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, Maintains Neutral Rating [Yahoo! Finance]
Low
Report
Citi Lowers Price Target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, Maintains Neutral Rating [Yahoo! Finance]
2/2
10:00 am
arct
Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets [Yahoo! Finance]
Low
Report
Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets [Yahoo! Finance]
1/24
06:28 am
arct
Arcturus Therapeutics (NASDAQ:ARCT) was upgraded by analysts at Roth Mkm to a "strong-buy" rating.
Low
Report
Arcturus Therapeutics (NASDAQ:ARCT) was upgraded by analysts at Roth Mkm to a "strong-buy" rating.
1/23
05:06 am
arct
Arcturus Therapeutics (NASDAQ:ARCT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Arcturus Therapeutics (NASDAQ:ARCT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/22
05:08 pm
arct
Arcturus Therapeutics (NASDAQ:ARCT) is now covered by analysts at Roth Mkm. They set a "buy" rating on the stock.
Medium
Report
Arcturus Therapeutics (NASDAQ:ARCT) is now covered by analysts at Roth Mkm. They set a "buy" rating on the stock.
1/10
03:09 pm
arct
1 Under-$10 Stock Set to Surge as Much as 963% in 2026 [Yahoo! Finance]
High
Report
1 Under-$10 Stock Set to Surge as Much as 963% in 2026 [Yahoo! Finance]
1/8
05:47 pm
arct
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/8
05:30 pm
arct
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/6
01:58 pm
arct
Arcturus Therapeutics (NASDAQ:ARCT) had its price target lowered by analysts at Citigroup Inc. from $9.00 to $7.00. They now have a "neutral" rating on the stock.
Low
Report
Arcturus Therapeutics (NASDAQ:ARCT) had its price target lowered by analysts at Citigroup Inc. from $9.00 to $7.00. They now have a "neutral" rating on the stock.
1/6
06:21 am
arct
Alloy Therapeutics Appoints Christian Cobaugh, Ph.D., as CEO of Alloy Genetic Medicines [Yahoo! Finance]
Low
Report
Alloy Therapeutics Appoints Christian Cobaugh, Ph.D., as CEO of Alloy Genetic Medicines [Yahoo! Finance]